“We are thrilled about this investment by Woodford Investment
Management.It is a testament to our technology platform and the
market opportunities that exist in the areas of dermatology and pain
management. The capital will allow us to accelerate the growth of our
Refinity aesthetic brand, our TriCalm® OTC dermatology brand as well as
our drug development programs,” said Cosmederm Bioscience CEO, Sean
Edwards.

About Cosmederm Bioscience

Cosmederm Bioscience is a specialty pharmaceutical company focused on
dermatology and pain management. The Company currently operates in the
areas of aesthetic medicine with its Refinity
Skin Science brand and in OTC dermatology with its TriCalm
brand. Cosmederm Bioscience is also developing topical prescription
drugs targeting inflammatory dermatologic conditions and neuropathic
pain. For more information, please visit www.cosmederm.com.